Skip to main content

Skimune® Epi

Are you looking for an OECD guideline validated epidermal model for toxicology or irritation testing?

Are you looking for a defined model with quick turnaround for hazard identification?

Are you looking for a more high throughput screening assay to risk assess chemicals, compounds, novel drugs and biologics?

Skimune® Epi – in vitro reconstructed Human epidermis

Alcyomics have developed an in vitro model of the human epidermis displaying characteristic histology and protein expression. Skimune® Epi offers end users an alternative to animal tests as the platform is fully humanised and cultured using a tissue culture scaffold as opposed to animal-based collagen material. Reduced reliance on animal products helps maintain batch consistence and improve result variance.

This provides a robust testing platform for epidermal irritation and toxicity studies. We have also developed this model to identify toxicological endpoints such as dose toxicity, cell viability, apoptosis and necrosis and the effects of test compounds or drugs on cytokines, growth factors and chemokine levels.

 


 

Figure 1: Skimune® Epi shows histotypical protein expression of the human epidermis.

Immunofluorescence staining for A) Cytokeratin 10 (Red), Cytokeratin 1 (Green), B) Involucrin (Red), Integrin Alpha 6 (Green), C) Filaggrin.

These results demonstrate the clear similarities to human epidermis.

Figure 1

Figure 1

 


 

Figure 2: SDS assessment of Skimune® Epi.

SDS barrier testing dynamics demonstrate the reliability of our assay and its similarities to other OECD #439 validated and approved epidermal model assays.

 


 

Figure 3: Comparing Skimune®Epi to other OECD #439 test protocols.

Skimune® Epi was capable of correctly identifying the hazard classification of 4 model compounds. Data shows excellent correlation with other OECD #439 regulated test protocols.

Figure 3

Figure 3


 

Key Benefits

  • Fully humanised 3D epithelial model.
  • Fully tailorable to clients needs with the capacity for additional cell types, culture formats characterisation techniques etc. to best suit your research needs.
  • Solves the problem of the ban on animal testing for cosmeceuticals – 7th Amendment to the Cosmetics Directive (EU Directive 76/768/EEC2), March 2009/2013.
  • Reduces development costs.
  • Increases product safety profile.

For more information on the Skimune® Epi platform and how it can help your business please contact us

  • This form collects your name and email so what we can add your to our newsletter list and send you relevant updates via email. Read our privacy policy for details on how we manage your data.